Bioxytran Inc (BIXT)

[Ecomike]

Pretty awesome news folks. We are waiting to find out FDA time lines, but my gut (and understanding of the bio-chemistry) says this could be the next Moderna blow out in 1-2 years. All depends on the trial timelines, and Covid19 variants. But BA 5 Covid19 is already as contagious as the measles and CDC/FDA and folks on the hot seat will be funding all sorts of opportunities and helping to get new solutions rushed to market (Limited delays, using the EUA trial process, that cuts 5-10 years off of trials...)

I called the rally on Moderna in March 2020. And Moderna rallied 10X higher than even I expected. And Moderna had hundred of millions of looses, trading on the big boards...

Omicron has out maneuvered the vaccines and adapted over time. And Antivirals like Pfizer's Paxlovid are getting their turn, but if BIXT's stuff works in 3 days with out a rebound, that will be huge.

We still need and FDA EUA trial, and they take time. But even now, IMO, this looks undervalued, 100 to 200% undervalued already even at this stage.

https://sciencescholar.us/journal/index.php/ijhs/article/view/10033

https://www.nejm.org/doi/full/10.1056/NEJMc2206576

Six months after the initial two BNT162b2 immunizations, the median neutralizing antibody pseudovirus titer was 124 against WA1/2020 but less than 20 against all the tested omicron subvariants (Figure 1B). Two weeks after administration of the booster dose, the median neutralizing antibody titer increased substantially, to 5783 against the WA1/2020 isolate, 900 against the BA.1 subvariant, 829 against the BA.2 subvariant, 410 against the BA.2.12.1 subvariant, and 275 against the BA.4 or BA.5 subvariant.

These data show that as compared with the response against the WA1/2020 isolate, the neutralizing antibody titer was lower by a factor of 6.4 against BA.1, by a factor of 7.0 against BA.2, by a factor of 14.1 against BA.2.12.1, and by a factor of 21.0 against BA.4 or BA.5.

In addition, as compared with the median neutralizing antibody titer against the BA.1 subvariant, the median titer was lower by a factor of 2.2 against the BA.2.12.1 subvariant and by a factor of 3.3 against the BA.4 or BA.5 subvariant.
Conclusion, Omicron BA 4 and 5 are winning. and are just as contageous as the measles
*
Among the participants with a history of Covid-19, the median neutralizing antibody titer was 11,050 against the WA1/2020 isolate, 1740 against the BA.1 subvariant, 1910 against the BA.2 subvariant, 1150 against the BA.2.12.1 subvariant, and 590 against the BA.4 or BA.5 subvariant

(even natural immunity from prior infections is not high enough for BA 5)
*
These data show that the BA.2.12.1, BA.4, and BA.5 subvariants substantially escape neutralizing antibodies induced by both vaccination and infection. Moreover, neutralizing antibody titers against the BA.4 or BA.5 subvariant and (to a lesser extent) against the BA.2.12.1 subvariant were lower than titers against the BA.1 and BA.2 subvariants, which suggests that the SARS-CoV-2 omicron variant has continued to evolve with increasing neutralization escape. These findings provide immunologic context for the current surges caused by the BA.2.12.1, BA.4, and BA.5 subvariants in populations with high frequencies of vaccination and BA.1 or BA.2 infection.